Article

Choice of antifibrotic agent depends on risk of bleb failure

New York—Patients undergoing primary trabeculectomy who are at high risk for bleb failure should be treated with either a single application of mitomycin-C (MMC; Mutamycin, Bristol-Myers Oncology) or 5-fluorouracil (5-FU) intraoperatively followed by subconjunctival injection of 5-FU later, reported glaucoma specialist Celso Tello, MD.

"Although 5-FU and MMC increase the success of glaucoma filtering surgery by inhibiting fibroblast proliferation, MMC is more effective in preventing wound healing," explained Dr. Tello, assistant professor of ophthalmology, New York Medical College, New York Eye & Ear Infirmary, New York.

He explained the differences between the two antifibrotic agents during the glaucoma subspecialty day meeting at the American Academy of Ophthalmology annual meeting.

A single application Both antifibrotic agents can be used intraoperatively, applied with the use of large sponges. The 5-FU is applied for approximately 5 minutes while MMC is limited to a 1- to 3-minute application to avoid potential postoperative complications.

The 5-FU can also be delivered as a subconjunctival injection postoperatively, Dr. Tello said.

In a study at Moorfields Eye Hospital, London, researchers found that intraoperative 5-FU application was as effective as 5-FU subconjunctival injections in controlling fibroblast proliferation, he noted.

Safety and efficacy Two clinical trials have been conducted to evaluate the safety and efficacy of MMC and 5-FU in primary trabeculectomy. Singh and colleagues published a report in Ophthalmology in 2000, and WuDunn and colleagues published one in the American Journal of Ophthalmology in 2002. Both studies found that MMC and 5-FU were equally effective in IOP reduction for patients undergoing primary trabeculectomy. It was noted, however, that more complications were seen in patients treated with MMC, Dr. Tello said.

Complications seen with either antifibrotic agent include late-onset bleb leaks, bleb-related endophthalmitis, and hypotony maculopathy secondary to overfiltration.

"But these complications are more commonly seen with MMC," he said.

Recommendations For patients who are at low risk for bleb failure, Dr. Tello recommends 5-FU (50 mg/ml) given as a single intraoperative application over a wide area of exposure for 5 minutes. For those patients at high risk for bleb failure, he suggests MMC (0.2 to 0.4 mg/ml) administered as a single application over a wide area of exposure for 1 to 3 minutes. He also said that 5-FU can be used as described above and then followed later by a supplemental subconjunctival injection of 5-FU as needed for high-risk cases.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.